每年研究成果
每年研究成果
- 5結果
搜尋結果
-
2021
Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study (BMC Pulmonary Medicine, (2021), 21, 1, (165), 10.1186/s12890-021-01530-6)
Huang, T. H., Kuo, C. W., Chen, C. W., Tseng, Y. L., Wu, C. L. & Lin, S. H., 2021 12月, 於: BMC Pulmonary Medicine. 21, 1, 193.研究成果: Comment/debate › 同行評審
開啟存取 -
2020
Correction: Role of integrin-linked kinase in regulating the protein stability of the MUC1-C oncoprotein in pancreatic cancer cells (Oncogenesis, (2017), 6, 7, (e359), 10.1038/oncsis.2017.61)
Huang, H. L., Wu, H. Y., Chu, P. C., Lai, I. L., Huang, P. H., Kulp, S. K., Pan, S. L., Teng, C. M. & Chen, C. S., 2020 2月 1, 於: Oncogenesis. 9, 2, 27.研究成果: Comment/debate › 同行評審
開啟存取 -
2019
Erratum: A novel derivative of betulinic acid, SYK023, suppresses lung cancer growth and malignancy (Oncotarget (2015) 6 (13671–13687) DOI: 10.18632/oncotarget.3701)
Hsu, T. I., Chen, Y. J., Hung, C. Y., Wang, Y. C., Lin, S. J., Su, W. C., Lai, M. D., Kim, S. Y., Wang, Q., Qian, K., Goto, M., Zhao, Y., Kashiwada, Y., Lee, K. H., Chang, W. C. & Hung, J. J., 2019, 於: Oncotarget. 10, 60, p. 6536-6537 2 p.研究成果: Comment/debate › 同行評審
-
2017
Corrigendum to “The role of hepassocin in the development of non-alcoholic fatty liver disease” (Journal of Hepatology (2013) 59(5) (1065–1072) (S0168827813004145) (10.1016/j.jhep.2013.06.004))
Wu, H. T., Lu, F. H., Ou, H. Y., Su, Y. C., Hung, H. C., Wu, J. S., Yang, Y. C., Wu, C. L. & Chang, C-J., 2017 2月 1, 於: Journal of Hepatology. 66, 2, p. 468 1 p.研究成果: Comment/debate › 同行評審
-
2006
Erratum: Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer (Clinical Cancer Research (2019) 12(5199–5206)Doi:10.1158/1078-0432.CCR-06-0429)
Kulp, S. K., Chen, C. S., Wang, D. S., Chen, C. Y. & Chen, C. S., 2006 9月 1, 於: Clinical Cancer Research. 25, 9, 1 p.研究成果: Comment/debate › 同行評審
開啟存取